Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

VJHemOnc is pleased to be a Media Partner for the 2023 Tandem Meetings ❘ Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, which are the combined annual meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR). These meetings featured the latest developments in the field of hematopoietic cell transplantation and cellular therapy.
View all videos

Tandem Meetings 2023

The Tandem Meetings I Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR®
15–19 February 2023 | Orlando, FL

Tandem Meetings 2023

The Tandem Meetings I Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR®
15–19 February 2023 | Orlando, FL
VJHemOnc is pleased to be a Media Partner for the 2023 Tandem Meetings ❘ Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, which are the combined annual meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR). These meetings featured the latest developments in the field of hematopoietic cell transplantation and cellular therapy.
View all videos

Latest videos

View all videos
2:07
Outcomes with CD34-selected stem cell boost for poor graft function and graft failure after alloSCT
Muhammad Umair Mushtaq • 17 Feb 2023
3:32
Phase II study of panobinostat/GemBuMel with autoSCT in high-risk or R/R multiple myeloma
Yago Nieto • 13 Feb 2023
2:17
The impact of checkpoint inhibitor-based salvage regimens in patients with R/R HL undergoing autoSCT
Sanjal Desai • 21 Jan 2023
3:41
Preliminary results from Phase I study of CD123 CAR-T therapy in pediatric R/R AML
Swati Naik • 20 Feb 2023

Late-breaking abstracts

View all
5:08
LBA: CD33 CRISPR/Cas9 gene-edited donor allograft in patients with AML at risk of relapse post-HSCT
John DiPersio • 21 Feb 2023
2:55
LBA: update on Phase I study of rapcabtagene autoleucel in patients with R/R DLBCL
Nirav Niranjan Shah • 15 Feb 2023
3:45
LBA: outcomes of children and young adults with B-ALL following tisa-cel reinfusion
Kevin McNerney • 24 Feb 2023
4:04
LBA: Phase III study of Iomab-B prior to allogeneic transplantation vs conventional care in R/R AML
Rajneesh Nath • 20 Feb 2023

Transplantation

View all
5:14
Global trends in the use of stem cell transplantation for AML
Molly Tokaz • 2 Mar 2023
2:22
The benefit of autologous transplantation in the era of novel agents in multiple myeloma
Muzaffar Qazilbash • 24 Feb 2023

CAR-T therapy

View all
7:35
Survey on the evaluation and management of DLBCL following suboptimal response to CAR-T therapy
Nausheen Ahmed • 20 Feb 2023
3:12
Safety & efficacy of LV20.19 CAR-T therapy in Richter’s transformation and R/R MCL
Nirav Niranjan Shah • 15 Feb 2023

Leukemia

View all
4:13
ALL highlights: tisa-cel reinfusion in B-ALL & targeting CD5 and CD7 with CAR-Ts in T-ALL
John DiPersio • 21 Feb 2023
3:11
Predictive factors for HLH toxicity in patients with B-ALL treated with tisa-cel
Kevin McNerney • 24 Feb 2023

Lymphoma

View all
3:23
Real-world outcomes of patients with transformed R/R DLBCL treated with CD19 CAR-T therapy
Swetha Kambhampati • 23 Feb 2023
6:01
Update on ALLELE: tab-cel in patients with EBV+ PTLD following alloSCT after rituximab failure
Amer Beitinjaneh • 22 Feb 2023
The content of VJHemOnc is intended for healthcare professionals